Infinity Pharmaceuticals, Inc. (INFI)

Infinity Pharmaceuticals, Inc. (INFI) — VMCI valuation read

INFI prints VMCI 40/100 inside the Healthcare sector, where the median sits at 50. The 11-point below-median delta is the cleanest single-number summary of Infinity Pharmaceuticals, Inc.'s composite stance, and in the mid-cap bucket it places the share behind the typical peer on the five-pillar mix.

On INFI, the SEC EDGAR Form 4 stream shows no insider buys or sells in the past 30 days. Quiet tapes happen; they just remove a signal that bull and bear cases sometimes lean on for confirmation.

**Investor frame.** INFI trades at 16.0x earnings, 11% below the Healthcare median of 18.0x; that is the value line. ROIC of 18.0% sits 8.0pp above the Healthcare median (10.0%); that is the quality line. net debt to EBITDA of 1.1x leaves covenant headroom; that is the risk line for Infinity Pharmaceuticals, Inc. on the trailing financials.

INFI fell 3.6% over the trailing 7 days, with a -21.3% read on a 30-day basis.